How to reconstitute Sirolimus Rx: a step by step guide

Last updated 2026-07-27

What does "reconstitute" actually mean for Sirolimus Rx?

Reconstitution just means turning a powder back into a liquid you can measure and dose. Sirolimus Rx ships from the fulfilling compounding pharmacy as a lyophilized (freeze-dried) powder in a sterile vial, because rapamycin in solid form is far more stable on the shelf and during shipping than a premixed liquid. Once you add the diluent, the clock starts on its stability, so nobody wants that step happening at a warehouse three weeks before it reaches you. Sirolimus and rapamycin are the same molecule, just two names for it: rapamycin was the original name after Rapa Nui (Easter Island), where the source bacterium was found, and sirolimus is the generic drug name the FDA uses on labels for the approved oral tablet and solution (Rapamune) ^[1]. Whether your vial says "sirolimus" or "rapamycin," the chemistry inside is identical. The reconstituted product is not a new drug. It's the same active compound now dissolved in a carrier liquid at a specific milligram-per-milliliter concentration, which is what lets you actually draw up a precise, small dose. Compounded sirolimus for off-label longevity use is typically dosed once weekly or every 5 to 14 days, at doses far below the daily transplant-rejection-prevention doses studied in FDA trials, which is one more reason precise reconstitution and measurement matters: the margin for dosing error is smaller when the target dose itself is small ^[2].

What supplies do I need before I start?

Lay everything out before you crack the vial. You want the vial of lyophilized powder, the correct diluent (usually sterile water for injection or bacteriostatic water, per your pharmacy's instructions), alcohol swabs, a syringe sized appropriately for the diluent volume (commonly 1 to 3 mL), and a separate fine-gauge syringe for the actual dose once the solution is made. Don't improvise the diluent. Some compounded formulations specify bacteriostatic water (which contains 0.9% benzyl alcohol as a preservative, allowing multi-dose use over a longer window) versus plain sterile water for injection, which has no preservative and is generally meant for single-use or fast turnover ^[3]. Using the wrong one can shorten shelf life or, worse, introduce a preservative sensitivity issue for some users. If the label that came with your vial does not match what you were expecting, call the pharmacy before you mix anything. Work on a clean, flat, well-lit surface. Wash your hands. Wipe the vial tops with alcohol and let them air dry for a few seconds, don't blow on them or wave them dry, that reintroduces contamination risk.

What is the actual step-by-step reconstitution process?

The exact volumes always come from your specific pharmacy's compounding sheet, because different labs formulate different target concentrations. But the mechanical steps are consistent across almost every lyophilized-powder reconstitution: 1. Confirm the vial label matches what you expect (drug name, strength, lot number, expiration date). 2. Swab both the powder vial stopper and the diluent vial stopper with alcohol; let dry. 3. Draw up the exact diluent volume specified on your instructions using a clean syringe. 4. Insert the needle into the powder vial at an angle, aiming the stream at the vial wall rather than directly onto the powder, and inject slowly. 5. Remove the needle and gently swirl the vial between your palms. Do not shake it. Shaking introduces air bubbles and can degrade or denature the compound, and with lyophilized biologics and small molecules alike, foaming can also make it hard to draw an accurate dose afterward. 6. Let the vial sit for the time stated on your instructions (often a few minutes) to let any foam settle and full dissolution finish. 7. Inspect the solution: it should be clear, without visible particles or cloudiness. If it looks off, don't use it, call the pharmacy. 8. Label the vial immediately with the reconstitution date and time, and the calculated concentration. Step 8 is the one people skip and regret. A month from now you will not remember whether you mixed it on a Tuesday or the following Sunday, and beyond-use dating is not optional guesswork, it's a real pharmaceutical stability limit.

How do I calculate the concentration after mixing?

Concentration after reconstitution equals total milligrams of drug in the vial divided by total mL of liquid once diluent is added. If your vial contains 5 mg of lyophilized sirolimus and your instructions say to add 2.5 mL of diluent, you get 5 mg / 2.5 mL = 2 mg/mL. That's the number you use for every dose calculation going forward with that vial. This is exactly the kind of arithmetic worth double-checking against a second source rather than doing once in your head at the kitchen counter. If you want the actual math worked through for your specific vial strength and target dose, the Sirolimus Rx dosage calculator walks through it, and the general Sirolimus Rx dosage page covers how typical off-label weekly doses are chosen relative to studied ranges. Write the concentration on the vial in permanent marker. Do this even if you're confident you'll remember. You won't, three weeks from now, at 9pm, tired.

How long is reconstituted Sirolimus Rx good for, and how should I store it?

Once mixed, refrigerate the vial at 2 to 8°C (36 to 46°F) unless your pharmacy's sheet says otherwise, and use it within the beyond-use date printed on your specific instructions. Compounded liquid formulations commonly carry beyond-use dates ranging from about 14 to 28 days under refrigeration, though this varies by pharmacy, diluent choice, and formulation, so treat any number you find online as a general range, not your specific answer. Your compounding pharmacy sets the actual date based on USP compounding standards, and that's the one that governs your vial ^[4]. Don't freeze it unless explicitly told to. Freezing and thawing cycles can degrade protein and small-molecule formulations in ways that aren't visible to the eye, so a solution can look fine and still have lost potency. Keep it away from light. Sirolimus is light-sensitive, which is part of why source vials often come in amber glass or wrapped, and why some compounding instructions tell you to keep the vial in its box or wrapped in foil between doses. Once a vial is past its beyond-use date, throw it out. There is no visual test that tells you a solution has lost 15% of its potency. You won't be able to tell by looking, and under-dosing an already-low weekly dose defeats the point of dosing at all.

What if the solution looks cloudy, has particles, or won't fully dissolve?

Don't use it, and don't try to fix it yourself. A cloudy solution, visible flecks, or a persistent film after appropriate swirling and settling time are all reasons to call the pharmacy that compounded it before drawing up a dose. This applies whether it happened right after mixing or a week into storage. Common causes include: using the wrong diluent, adding diluent too fast (creating localized concentration issues before full mixing), a vial that got shaken instead of swirled, or a temperature excursion during shipping that partially degraded the powder before you even opened it. Any of these is a reason to request a replacement vial rather than push through and inject something you're not sure about. This is also why the shipping chain matters. A reputable, provider-reviewed source means the vial you receive came from a licensed compounding pharmacy following USP <795> and <797> standards for sterile and non-sterile compounding, not an unregulated overseas seller with no chain of custody on temperature control ^[5].

Do I inject it, take it orally, or both, and does that change reconstitution?

Sirolimus is FDA-approved as an oral tablet and oral solution (Rapamune) for kidney transplant rejection prophylaxis; the FDA-approved formulation is swallowed, not injected ^[2]. Compounded versions used off-label for longevity protocols may be prepared as a reconstituted solution intended for oral use, and separately, some formulations are prepared for subcutaneous injection, depending on what your prescriber and pharmacy set up. The reconstitution steps above are broadly similar either way, but the intended route determines needle gauge, syringe type, and whether you need an oral dosing syringe versus an injection needle. If your protocol involves injection, see Sirolimus Rx how to inject and Sirolimus Rx injection sites for the mechanics of that step, since injection technique carries its own risks (site rotation, infection risk, bruising) separate from reconstitution accuracy. Never assume route interchangeability on your own. If your vial and instructions were prepared for oral use, don't decide to inject it, and vice versa. Sterility assurance and excipients differ by intended route, and a solution compounded for oral use is not necessarily sterile enough or formulated correctly for injection.

Why does none of this come with an FDA label for longevity use?

Because there isn't one. Sirolimus is FDA-approved only for specific indications: prophylaxis of organ transplant rejection (oral Rapamune), and as Fyarro and Hyftor for certain rare conditions (a form of soft tissue sarcoma and facial angiofibromas from tuberous sclerosis, respectively) . There is no FDA-approved indication for aging, lifespan extension, or "longevity," and every low-dose, intermittent-dosing protocol discussed in the longevity community is off-label use, prescribed at a doctor's discretion, not FDA-sanctioned for that purpose. The animal data behind the excitement is real and it's strong. The National Institute on Aging's Interventions Testing Program (ITP), running rapamycin trials across genetically diverse mice at multiple sites since 2006, has repeatedly found that rapamycin extends median lifespan in both sexes, with effects seen even when dosing started later in life, and effect sizes in some cohorts reaching roughly 10 to 26% depending on dose, sex, and start age . That is genuinely one of the more reproducible findings in mouse aging research. What does not exist is a completed human randomized controlled trial showing rapamycin extends human lifespan or healthspan. None. Every claim you see about human longevity benefit is extrapolation from mouse and cell data, plus short-term human biomarker studies (things like the PEARL trial looking at safety and some functional measures over six months), not a mortality endpoint trial in humans . That gap is the single most important thing to hold onto when reading anything about rapamycin and aging, reconstitution advice included: you're carefully and precisely dosing a drug whose long-term human lifespan effect is still unproven, however promising the rodent data looks.

What are the real risks I should know before I even reconstitute a dose?

Sirolimus is an immunosuppressant. That is not a side note, it's the core pharmacology, and it's why the FDA approved it in the first place, to stop transplant organ rejection by suppressing immune response ^[2]. At the low, intermittent doses used in most off-label longevity protocols, immune suppression appears to be less pronounced than at daily transplant doses, but "less" is not "none," and people on any sirolimus dose should expect somewhat slower wound healing and higher infection susceptibility, and should tell any treating physician or dentist that they're taking it. Mouth ulcers (stomatitis) are one of the most commonly reported side effects across sirolimus studies, including at lower doses used in trials like PEARL, where oral mucositis was among the more frequent adverse events reported . They're usually manageable but can be genuinely uncomfortable, and some users adjust dose or timing around them under physician guidance. Metabolic effects are also real and worth monitoring: sirolimus can raise triglycerides and cholesterol and has been associated with new-onset or worsened insulin resistance in some patients, effects well documented in the transplant literature at therapeutic daily doses and still a monitoring point at lower intermittent doses ^[2]. Anyone on a sirolimus protocol, longevity-motivated or not, should have baseline and periodic lipid panels and fasting glucose checked, more than take the drug and assume the mouse data translates cleanly. None of this is a reason to panic, but it is a reason reconstitution and dosing precision matter. Getting concentration math wrong on a drug with a genuine risk profile is not a rounding error you want to make.

How does dosing frequency affect how much reconstituted solution I use per session?

Most off-label longevity protocols use intermittent dosing, commonly once weekly, rather than the daily dosing used for transplant patients, based partly on the mouse ITP data showing intermittent, pulsed mTOR inhibition may achieve benefit while limiting some side effects, though again, that inference comes from rodent studies plus mechanistic reasoning about mTOR biology, not confirmed human outcome data . Because dosing is intermittent, and each reconstituted vial has a limited beyond-use date, most people are reconstituting enough solution to cover a certain number of doses within that window, then reconstituting a new vial. If your dosing interval is longer than your vial's safe-use window, you may need a fresh vial each cycle rather than trying to stretch one further than the pharmacy's dating supports. How this maps onto an actual weekly schedule, and how cycle length interacts with the drug's roughly 57 to 63 hour terminal half-life in whole blood (per Rapamune's FDA label pharmacokinetic data), is covered in more depth on Sirolimus Rx cycle length and Sirolimus Rx half life ^[2]. The half-life is part of why once-weekly dosing became the common off-label pattern discussed in the field, it lines up with how long the drug takes to clear.

What mistakes do people actually make when reconstituting at home?

The most common one is eyeballing diluent volume instead of measuring it in a syringe. A rough pour or a "close enough" measurement changes your final concentration and every dose calculation downstream. Always use a syringe to measure diluent, never a dropper or estimate. Second most common: shaking the vial. It feels intuitive, powder plus liquid, shake to mix, but shaking a lyophilized compound can cause foaming, protein or compound stress, and inaccurate draw volumes from air pockets. Swirl gently instead, and give it the settling time your instructions specify. Third: not labeling the vial with date and concentration. This leads directly to using an expired or unknown-concentration solution weeks later, at exactly the moment when it's hardest to reconstruct what you actually did. Fourth: reusing needles or not swabbing vial tops between draws, which raises contamination risk on a vial you may be drawing from multiple times over its beyond-use window. Use a fresh needle for each draw where practical, and always swab the stopper before inserting a needle, every single time, more than the first. Fifth, and this one is about the bigger picture: treating reconstitution precision as the main safety issue while skipping the actual medical oversight. Correct math and clean technique matter, but they don't substitute for a prescribing physician who's reviewed your labs, your health history, and whether sirolimus is appropriate for you at all.

Where should the vial and prescription actually come from?

From a licensed pharmacy, tied to an actual prescriber, with clear labeling and reconstitution instructions specific to that batch. That's not a brand pitch, it's the baseline safety bar, because compounded sirolimus obtained outside that chain has no guaranteed potency, sterility, or accurate labeling, and dosing errors compound (no pun intended) when you don't know what's actually in the vial. Sirolimus Rx works with a provider-reviewed process where a licensed physician reviews the request and a fulfilling compounding pharmacy prepares and ships the vial with matched instructions, rather than a reader sourcing raw rapamycin powder from an unregulated seller and guessing at diluent ratios. If you're evaluating whether low-dose rapamycin makes sense for you at all, that's a conversation for a physician who can review your labs and history, not a reconstitution guide, however carefully written. Whatever your source, keep the paper instructions that came with your specific vial. Generic guidance like this article explains the why behind each step, but your printed sheet, matched to your exact concentration and diluent, is the document that actually governs your vial.

Frequently asked questions

What diluent should I use to reconstitute Sirolimus Rx?

Use exactly what your compounding pharmacy's instructions specify, typically either sterile water for injection or bacteriostatic water. They are not interchangeable: bacteriostatic water contains a preservative that affects shelf life and multi-dose safety, while sterile water does not. Never substitute one for the other without calling the pharmacy first.

Can I shake the vial to mix the powder faster?

No. Shaking introduces air bubbles and foam, which can stress the compound and make it hard to draw an accurate dose. Gently swirl the vial between your palms instead, and let it sit for the settling time stated in your instructions before drawing up a dose.

How long does reconstituted sirolimus last in the fridge?

It depends on your specific formulation, but compounded liquid preparations commonly carry beyond-use dates in the range of roughly 14 to 28 days under refrigeration (2 to 8°C). Your pharmacy sets the exact date under USP compounding standards; that printed date, not an online estimate, governs your vial.

Is sirolimus the same thing as rapamycin?

Yes. Rapamycin is the original name for the compound, discovered from a bacterium found on Rapa Nui (Easter Island); sirolimus is the generic drug name used on FDA labels. They refer to the same molecule and are used interchangeably in scientific and clinical literature.

Has rapamycin been proven to extend human lifespan?

No completed human trial has shown rapamycin extends human lifespan. The strongest evidence is from the NIA Interventions Testing Program in mice, showing consistent median lifespan extension. Human studies so far, like the PEARL trial, have looked at short-term safety and biomarkers over months, not mortality outcomes over years.

What does the FDA actually approve sirolimus for?

The FDA approves oral sirolimus (Rapamune) for prevention of organ transplant rejection, and separate formulations, Fyarro and Hyftor, for a rare soft tissue sarcoma and for facial angiofibromas from tuberous sclerosis. There is no FDA-approved use for aging or lifespan extension; all longevity use is off-label.

What are the main risks of taking low-dose sirolimus for longevity?

Sirolimus is an immunosuppressant, so infection risk and slower wound healing are real even at low intermittent doses. Mouth ulcers are one of the most commonly reported side effects. Metabolic effects like elevated triglycerides, cholesterol, and insulin resistance are also documented and worth monitoring with periodic bloodwork.

Do I inject reconstituted sirolimus or take it by mouth?

It depends on what your prescriber and pharmacy prepared. FDA-approved sirolimus (Rapamune) is oral. Some compounded off-label preparations are formulated for oral use, others for subcutaneous injection. Don't switch routes on your own; sterility and formulation differ by intended route, and your instructions specify which one applies to your vial.

What should I do if my reconstituted solution looks cloudy or has particles?

Don't use it. Call the compounding pharmacy that prepared it and describe exactly what you see. Cloudiness or visible particles can indicate wrong diluent, improper mixing, or a temperature excursion during shipping, and any of these is a reason to request a replacement vial rather than inject it.

Why is sirolimus dosed weekly instead of daily for longevity protocols?

Most off-label longevity protocols use intermittent, often once-weekly dosing, partly reflecting mouse studies suggesting pulsed mTOR inhibition may separate benefit from side effects, and partly reflecting the drug's roughly 57 to 63 hour half-life. This differs from the daily dosing used for transplant patients and remains unconfirmed in human outcome trials.

How do I calculate the concentration of my reconstituted vial?

Divide the total milligrams of drug in the vial by the total milliliters of liquid after adding diluent. A 5 mg vial mixed with 2.5 mL of diluent yields 2 mg/mL. Always write this number and the mixing date on the vial immediately so you don't have to recalculate or guess later.

Can I freeze reconstituted sirolimus to make it last longer?

Not unless your pharmacy's instructions explicitly say to. Freeze-thaw cycles can degrade the compound in ways you can't see, and a solution that looks fine after thawing may have lost potency. Store it refrigerated at 2 to 8°C and use it within the stated beyond-use date instead.

Sources

1. USP, General Chapter <795> Pharmaceutical Compounding - Nonsterile Preparations overview: USP compounding standards govern beyond-use dating for compounded nonsterile preparations
2. USP, General Chapter <797> Pharmaceutical Compounding - Sterile Preparations overview: USP <797> sets sterility and quality standards for sterile pharmaceutical compounding
3. Harrison DE, Strong R, Sharp ZD, et al. "Rapamycin fed late in life extends lifespan in genetically heterogeneous mice." Nature. 2009;460(7253):392-395.: The NIA Interventions Testing Program found rapamycin extends median lifespan in genetically heterogeneous mice, including when started later in life
4. Miller RA, Harrison DE, Astle CM, et al. "Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice." J Gerontol A Biol Sci Med Sci. 2011;66(2):191-201.: Rapamycin lifespan extension effects in mice vary by dose, sex, and age at treatment start across multiple ITP test sites
5. Kaeberlein TL, et al. "Evaluation of a rapamycin-based dietary supplement for healthy older adults (PEARL trial)." GeroScience. 2023.: Short-term human studies of low-dose rapamycin have examined safety and biomarkers, not lifespan or mortality outcomes, and reported oral mucositis as a common adverse event